BBVA USA Bancshares’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
$606K Sell
7,245
-186
-3% -$15.7K 0.03% 371
2020
Q4
$678K Buy
7,431
+1,794
+32% +$149K 0.03% 346
2020
Q3
$449K Sell
5,637
-4
-0.1% -$312 0.03% 376
2020
Q2
$389K Sell
5,641
-212
-4% -$15.1K 0.02% 403
2020
Q1
$368K Sell
5,853
-792
-12% -$57.1K 0.03% 373
2019
Q4
$517K Buy
+6,645
New +$519K 0.03% 366
2019
Q3
Sell
-6,843
Closed -$422K 425
2019
Q2
$422K Buy
6,843
+1,293
+23% +$78.2K 0.03% 394
2019
Q1
$354K Buy
5,550
+777
+16% +$44.3K 0.02% 418
2018
Q4
$244K Sell
4,773
-756
-14% -$38.3K 0.02% 448
2018
Q3
$321K Buy
+5,529
New +$270K 0.02% 448
2017
Q4
Sell
-7,959
Closed -$290K 536
2017
Q3
$290K Sell
7,959
-621
-7% -$23.7K 0.02% 458
2017
Q2
$338K Buy
8,580
+276
+3% +$10.1K 0.02% 432
2017
Q1
$260K Buy
8,304
+1,893
+30% +$59.3K 0.02% 488
2016
Q4
$200K Buy
6,411
+606
+10% +$19.6K 0.01% 535
2016
Q3
$233K Buy
+5,805
New +$219K 0.02% 512

Other funds holding EW

BBVA USA Bancshares's EW Position: Q1 2021 in Review

BBVA USA Bancshares reduced its Edwards Lifesciences (EW) stake by 2.5% in Q1 2021, selling an estimated $15.7K and leaving 7,245 shares worth $606K. The position accounts for 0.03% of the portfolio, ranked #371.

BBVA USA Bancshares first reported a position in EW in Q3 2016 and has held it in 15 quarters since. The position peaked at $678K in Q4 2020. 1,144 funds tracked by Wall St. Rank hold EW as of Q1 2021.

  • BBVA USA Bancshares held 7,245 shares of Edwards Lifesciences worth $606K as of Q1 2021.
  • BBVA USA Bancshares sold 186 Edwards Lifesciences shares in Q1 2021, an estimated $15.7K.
  • Edwards Lifesciences made up 0.03% of BBVA USA Bancshares's portfolio in Q1 2021, its #371 holding.
  • BBVA USA Bancshares first reported a position in Edwards Lifesciences in Q3 2016 and has held it in 15 quarters since.
  • BBVA USA Bancshares's Edwards Lifesciences position peaked at $678K in Q4 2020.
  • 1,144 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2021.

Based on BBVA USA Bancshares's 13F filing for Q1 2021, filed 23 Apr 2021.